The latest on artificial intelligence transforming medicine

Lilly’s model-sharing deal with 1STBIO could widen the gap in AI drug discovery

Eli Lilly’s decision to grant Korean biotech 1STBIO access to proprietary AI drug-discovery models is a notable sign of how valuable internal model assets have become. The deal is also a reminder that partnerships may increasingly revolve around who controls the best predictive systems, not just the best data.